for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MacroGenics Inc

MGNX.OQ

Latest Trade

14.44USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

13.50

 - 

36.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.44
Open
--
Volume
--
3M AVG Volume
9.70
Today's High
--
Today's Low
--
52 Week High
36.40
52 Week Low
13.50
Shares Out (MIL)
61.26
Market Cap (MIL)
884.57
Forward P/E
-4.45
Dividend (Yield %)
--

Next Event

Q4 2021 MacroGenics Inc Earnings Release

Latest Developments

More

MacroGenics Reports Qtrly Loss Per Share Of 86 Cents

MacroGenics Says Preliminary Clinical Results From Phase 1 Cohort Expansion Of The Ongoing Mgc018 Study Presented At ESMO 2021 Virtual Annual Congress

MacroGenics Announces Survival Results From Study Of Margenza In Patients With Her2-Positive Metastatic Breast Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MacroGenics Inc

MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company's lead product, MARGENZA, is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. In addition, the Company has a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, such as Flotetuzumab (CD123 x CD3), Retifanlimab (PD-1), Enoblituzumab (anti-B7-H3), Tebotelimab (PD-1 x LAG-3), MGD019 (PD-1 x CTLA-4), MGC018 (B7-H3), IMGC936 (ADAM9) and MGD014 (HIV x CD3). These pipelines are created primarily using its antibody-based technology platforms.

Industry

Biotechnology & Drugs

Contact Info

9704 Medical Center Dr

ROCKVILLE, MD

20850-3343

United States

+1.301.2515172

https://www.macrogenics.com/

Executive Leadership

Paulo F. Costa

Independent Chairman of the Board

Scott Koenig

President, Chief Executive Officer, Director

James Karrels

Chief Financial Officer, Senior Vice President, Corporate Secretary

Ezio Bonvini

Senior Vice President - Research, Chief Scientific Officer

Stephen L. Eck

Senior Vice President, Clinical Development and Chief Medical Officer

Key Stats

1.70 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-4.190

2019

-3.160

2020

-2.470

2021(E)

-3.244
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.63
Price To Book (MRQ)
3.04
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-45.15
Return on Equity (TTM)
-38.14

Latest News

Latest News

U.S. FDA approves MacroGenics' breast cancer drug

MacroGenics Inc said on Wednesday the U.S. Food and Drug Administration (FDA) had approved its drug Margenza in combination with chemotherapy for the treatment of an advanced type of breast cancer in patients who failed two or more prior therapies.

U.S. FDA approves MacroGenics' breast cancer drug

MacroGenics Inc said on Wednesday the U.S. Food and Drug Administration (FDA) had approved its drug Margenza in combination with chemotherapy for the treatment of an advanced type of breast cancer in patients who failed two or more prior therapies.

BRIEF-Macrogenics Announces Presentation Of Preclinical Data

* MACROGENICS ANNOUNCES PRESENTATION OF PRECLINICAL DATA AT THE 2020 AACR ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Macrogenics Says May Offer And Sell Shares Of Common Stock Having Additional Aggregate Offering Price Of Up To $125 Mln From Time To Time - SEC Filing

* MACROGENICS SAYS MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING ADDITIONAL AGGREGATE OFFERING PRICE OF UP TO $125 MILLION FROM TIME TO TIME - SEC FILING Source text: https://bit.ly/2NewJRq Further company coverage:

BRIEF-Macrogenics Appoints Stephen Eck As Chief Medical Officer

* MACROGENICS APPOINTS DR. STEPHEN ECK AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Macrogenics Reports Margetuximab Granted Orphan Drug Status For Gastric Cancer

* MACROGENICS ANNOUNCES MARGETUXIMAB GRANTED ORPHAN DRUG DESIGNATION IN THE U.S. FOR GASTRIC CANCER Source text for Eikon: Further company coverage:

BRIEF-Macrogenics Provides Update On FDA Review Of Margetuximab For Her2-Positive Metastatic Breast Cancer

* MACROGENICS PROVIDES UPDATE ON FDA REVIEW OF MARGETUXIMAB FOR HER2-POSITIVE METASTATIC BREAST CANCER

BRIEF-Macrogenics Announces Registration Study Of Flotetuzumab In Patients With Refractory Acute Myeloid Leukemia

* MACROGENICS ANNOUNCES REGISTRATION STUDY OF FLOTETUZUMAB IN PATIENTS WITH REFRACTORY ACUTE MYELOID LEUKEMIA

BRIEF-MacroGenics Announces Preliminary Clinical Results From MGD013 And MGC018 To Be Presented At ASCO Annual Meeting

* MACROGENICS ANNOUNCES PRELIMINARY CLINICAL RESULTS FROM MGD013 AND MGC018 TO BE PRESENTED AT THE ASCO ANNUAL MEETING

BRIEF-Macrogenics Provides Update On Corporate Progress And First Quarter 2020 Financial Results

* MACROGENICS PROVIDES UPDATE ON CORPORATE PROGRESS AND FIRST QUARTER 2020 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up